ARQULE

Codice
ARQL
Risorse esterne
Opinione della community
Prezzo Variazione Volume
1.2 -18.37 €
(-93.87%)
2450163
P/E Obiettivo ad 1anno
0 4.08 €

Compra - Vendi

0
Tutte le tue transazioni per questo titolo

Devi effettuare l'accesso


Grafico

Altri utenti che hanno investito

Transations in last week
Buy: 21
Sell : 11

ghed Nero2008 santo Simone Bonzanini

Commenti


Notizie

Trading Options During Earnings in ArQule Inc (NASDAQ:ARQL) - CML News

We're going to examine buying and selling out of the money strangles in ArQule Inc and find out once and for all what the winning trades have been during earnings releases. With the right tool kit it's easy to find an explicit answer: Selling out of ...altro » Leggi

ArQule, Inc. (NASDAQ:ARQL)'s Liver Cancer Drug Fails: What's Next? - Market Exclusive

ArQule, Inc. (NASDAQ:ARQL) took a real hit at the end of last week, as the company announced data from a late stage oncology trial. The data did not read out as hoped, and ArQule currently trades for a close to 20% discount to its Friday morning open ... Leggi

Biotech Stocks Worth Chasing: ArQule, Inc. (ARQL), Array BioPharma Inc. (ARRY) - The Independent Republic

ArQule, Inc. (ARQL) ended last trading session with a change of -18.37 percent. It trades at an average volume of 144.93K shares versus 2.45M shares recorded at the end of last trading session. The share price of $1.2 is at a distance of 0 percent from ... Leggi

US stocks higher at close of trade; Dow Jones Industrial Average up 0.02% - Investing.com

The worst performers were X T L Biopharmaceuticals Ltd (NASDAQ:XTLB) which was down 34.92% to 2.330 in late trade, ArQule Inc (NASDAQ:ARQL) which lost 18.37% to settle at 1.200 and Aoxin Tianli Group Inc (NASDAQ:ABAC) which was down 16.92% ...altro » Leggi

Daiichi, ArQule cancer drug fails in late-stage study - BioPharma Dive

... rights to tivantinib made up $60 million of that total. In late 2015, the companies agreed to co-commercialize the drug in the U.S.. Following news of the trial failure, ArQule stock plunged more than 18% to $1.20 per share in Friday morning trading. Leggi

The Top Three Holders Of ArQule, Inc. (ARQL) - Post Analyst

Multiple company employees have indulged in significant insider trading. ArQule, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director LOBERG MICHAEL D has acquired 3,719 shares of ArQule, Inc. (ARQL) ...altro » Leggi

ArQule Inc Realized Volatility Hits An Exceptional High - CML News

As a heads up, in the "Why This Matters" section at the end of this article on ArQule Inc (NASDAQ:ARQL) , we're going to take a step back and show really clearly that there is actually a lot less "luck" in successful option trading than most people are ...altro » Leggi

The NJ State Employees Deferred Compensation Plan Has $340000 Stake in ArQule Inc. (ARQL) - DailyQuint

Shares of ArQule Inc. (NASDAQ:ARQL) traded up 2.38% during midday trading on Friday, reaching $1.29. The company's stock had a trading volume of 316,699 shares. The stock's 50-day moving average price is $1.35 and its 200-day moving average price ...altro » Leggi

ArQule, Inc. (NASDAQ:ARQL) Annual Price Target At $2.5 - Markets Daily

For example, if an equity is trading around $60, and the firm recorded a bad quarter and experts lessen the price target to $50 from $70, it will generate selling activity and lessen the share price target around $50. ArQule, Inc. (NASDAQ:ARQL) has ...altro » Leggi

BUZZ-US STOCKS ON THE MOVE-Banks, Kraft, Mondelez, UnitedHealth, Arqule, Smucker, Hertz - Nasdaq

N>, down 0.9 pct at $247.17 premarket U.S. banks stocks, which have flourished in the so-called "Trump trade", fall on profit-taking as investors look for more clarity on President Trump's tax, regulation and trade policies. [nL4N1G23UK ...altro » Leggi